Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Benzinga Newsdesk www.benzinga.com Negative 85.1%

Neg 85.1% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.